Please login to the form below

Not currently logged in
Email:
Password:

Forxiga

This page shows the latest Forxiga news and features for those working in and with pharma, biotech and healthcare.

AZ data suggest SGLT2 inhibitors can reduce heart failure risk

AZ data suggest SGLT2 inhibitors can reduce heart failure risk

AZ data suggest SGLT2 inhibitors can reduce heart failure risk. Publishes real-world data for study involving Forxiga/Farxiga, Invokana and Jardiance. ... Now, AZ's study suggests that benefit is reproduced in a generalised, real-world setting and that

Latest news

  • Merck & Co and Pfizer take aim at diabetes with trio of new drugs Merck & Co and Pfizer take aim at diabetes with trio of new drugs

    The first SGLT2 inhibitor to be approved in the US was Johnson &Johnson's Invokana (canagliflozin) in 2013, while in Europe it was AstraZeneca's Forxiga/Farxiga (dapagliflozin) the previous year. ... J&J's Invokana franchise brought in $1.4bn in sales

  • New Jardiance label could boost sales by $1.7bn, says analyst New Jardiance label could boost sales by $1.7bn, says analyst

    Another SGLT1 inhibitor - Bristol-Myers Squibb/AstraZeneca's Forxiga/Farxiga (dapagliflozin) - is also in a cardiovascular outcomes trial that is not due to generate results until 2019.

  • AstraZeneca's Forxiga set to be recommended by NICE AstraZeneca's Forxiga set to be recommended by NICE

    AstraZeneca's Forxiga set to be recommended by NICE. The type 2 diabetes ‘ triple therapy’ is backed in draft guidance. ... The firm is looking to expand Forxiga into kidney disease and heart failure, where it has begun recruitment for phase II trials

  • AZ looks beyond diabetes with Forxiga trials AZ looks beyond diabetes with Forxiga trials

    AZ looks beyond diabetes with Forxiga trials. Will investigate dapagliflozin in kidney disease and heart failure. ... AstraZeneca has started a clinical trial programme to try to extend the use of its diabetes drug Forxiga into kidney disease and heart

  • Updated EMPA-REG data show Jardiance also protects kidney Updated EMPA-REG data show Jardiance also protects kidney

    The new data gives Jardiance another boost as it competes in the market against rival SGLT2 inhibitors Invokana (canagliflozin) from Johnson &Johnson and Bristol-Myers Squibb/AstraZeneca's Forxiga/Farxiga (dapagliflozin).

More from news
Approximately 16 fully matching, plus 48 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Secondly, growth is ebbing away from Forxiga (dapagliflozin), the first entrant of the DPP4s, which is actually growing slightly slower than Trajenta. ... Forxiga and Invokana (canagliflozin) appear to be reaching a plateau but at different lower levels.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... The potential

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics